The financial burden of cancer treatment is a well-established concern.1,2 Owing to cost sharing, even insured patients face financial burden and are at risk for worsened quality of life3 and increased mortality.4 Underinsured patients (those spending more than 10% of their income on health care costs) are a growing population,5 and are at risk given the looming heath policy and coverage changes on the horizon. In this setting, little is known about what expectations patients have regarding those costs and how those cost expectations might impact decision making.
After approval from the institutional review board at Duke University Medical Center, we conducted a cross-sectional survey study of financial distress and cost expectations among patients with cancer presenting for anticancer therapy. We enrolled a convenience sample of adult patients at a comprehensive cancer center and at 3 affiliated rural oncology clinics. Patients provided written informed consent and were compensated with $10 for completing the survey. Trained interviewers surveyed patients in person.
We abstracted the electronic health record for cancer diagnosis, stage, type of treatment, and duration of treatment at the time of enrollment. Demographics including race and income were obtained from the patient. Patient out-of-pocket expenses were based on patient’s best estimation of recent, averaged monthly costs. We surveyed patients about whether their actual costs met their expectations, and about how much they were willing to pay out-of-pocket for cancer treatment, not including insurance premiums. Financial distress was measured using a validated measure. We measured median relative cost of care, defined as monthly out-of-pocket costs divided by income. Expected financial burden, willingness to pay, and subjective financial distress were dichotomized to assess the impact of unexpected costs and high financial distress. We used hypothesis testing to examine variables associated with burden and distress. Multivariable logistic regression included specific variables of interest along with select variables found to be statistically significant in bivariate testing. Statistical analyses were performed using SAS software (version 9.4, SAS institute).
Of 349 consecutive patients approached, 300 were eligible and agreed to participate, and 3 withdrew (86% response rate). Of the 300 patients, 157 (52%) were men. Patient characteristics, income, and costs are described in the Table along with unadjusted analyses. Forty-nine (16%) patients reported high or overwhelming financial distress (score >7).
The median relative cost of care was 11%. The relative cost of care for patients with high or overwhelming distress was 31% vs 10% for those with no, low, or average financial distress. One hundred eighteen (39%) participants endorsed higher than expected financial burden from cancer care. In unadjusted analysis, unexpected burden was associated with being younger, unmarried, nonwhite, unemployed/not retired, having lower household income, higher costs, colorectal/breast cancer diagnosis, lower quality of life and higher financial distress (Table). In adjusted analysis, experiencing higher than expected financial burden was associated with high or overwhelming financial distress (OR, 4.78; 95% CI, 2.02-11.32; P < .01) and with decreased willingness to pay for cancer care (OR, 0.48; 95% CI, 0.25-0.95; P = .03).
More than one-third of insured cancer patients receiving anticancer therapy faced out-of-pocket costs that were greater than expected, and patients with the most distress were underinsured, paying almost one-third of their income in health care-related costs. Patients at risk for unexpected costs had less household income and faced higher out-of-pocket costs.
Facing unexpected treatment costs was associated with lower willingness to pay for care, even when adjusting for financial burden. This suggests that unpreparedness for treatment-related expenses may impact future cost-conscious decision making. Interventions to improve patient health care cost literacy might impact decision making. Indeed, the Institute of Medicine has listed cancer cost-related health literacy as a high priority for future research, and this priority has been included in the Center for Medicare and Medicaid’s Oncology Care Model.6 Future studies should test interventions for cost mitigation through shared decision making.
Corresponding Author: Fumiko Chino, MD, Department of Radiation Oncology, Duke University Medical Center, DUMC 3085, Durham, NC 27710 (email@example.com).
Accepted for Publication: May 25, 2017.
Published Online: August 10, 2017. doi:10.1001/jamaoncol.2017.2148
Author Contributions: Drs Zafar and Chino had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Chino, Peppercorn, Altomare, Zafar.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Chino, Peppercorn, Rushing, Kamal, Zafar.
Critical revision of the manuscript for important intellectual content: Peppercorn, Rushing, Kamal, Altomare, Samsa, Zafar.
Statistical analysis: Rushing, Samsa.
Obtained funding: Zafar.
Administrative, technical, or material support: Chino, Kamal, Altomare.
Study supervision: Zafar.
Conflict of Interest Disclosures: None reported.
Funding/Support: Dr Zafar was supported by the American Cancer Society and by institutional support from the Duke Cancer Institute.
Role of the Funder/Sponsor: The American Cancer Society had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Additional Contributions: We thank Jonathan Nicolla, MBA, Duke Clinical Research Institute, for his help with data collection. Mr Nicolla is a salaried member of the support staff of the Duke Clinical Research Institute.
SY. Full disclosure—out-of-pocket costs as side effects. N Engl J Med
. 2013;369(16):1484-1486.PubMedGoogle ScholarCrossref
et al. The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient’s experience. Oncologist
. 2013;18(4):381-390.PubMedGoogle ScholarCrossref
et al. Impact of financial burden of cancer on survivors’ quality of life. J Oncol Pract
. 2014;10(5):332-338.PubMedGoogle ScholarCrossref
et al. Financial insolvency as a risk factor for early mortality among patients with cancer. J Clin Oncol
. 2016;34(9):980-986.PubMedGoogle ScholarCrossref
Institute of Medicine. Delivering High-Quality Cancer Care: Charting a New Course for a System in Crisis. Washington, DC: National Academies Press; 2013.